Download presentation
Presentation is loading. Please wait.
Published byEthan Anderson Modified over 5 years ago
1
Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia
2
Panelists
4
Dallas Heart Study: Lipid Characteristics of African Americans With Nonsense Mutations in PCSK9
5
ARIC: PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk
7
SAR236553 Phase 2: Change in LDL-C at 4-Week Dosing Intervals on Atorvastatin
8
MENDEL: AMG 145 Phase 2 Monotherapy in Patients With Hypercholesterolemia
9
MENDEL: Effect of AMG 145 on Percentage Change in LDL-C From Baseline
10
LAPLACE-TIMI 57: Phase 2 AMG 145 in Combination With Statin in Patients With Hypercholesterolemia
11
LAPLACE-TIMI 57: Study Design
12
LAPLACE-TIMI 57: Effect of AMG 145 on Percentage Change in LDL-C From Baseline
13
LAPLACE-TIMI 57: Adverse Events
14
GAUSS: Phase 2 AMG 145 in Statin-Intolerant Patients
15
GAUSS: Baseline Characteristics
16
GAUSS: Effect of AMG 145 on Percentage Change in LDL-C From Baseline
17
GAUSS: Percentage of Patients Achieving LDL-C Goals
18
SAR236553 in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe─Phase 2
19
SAR236553: Change in LDL-C in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe
20
RUTHERFORD: Phase 2 AMG 145 in Patients With Heterozygous FH
21
RUTHERFORD: Effect of AMG 145 on Percentage Change in LDL-C From Baseline
22
AMG 145: Ongoing Phase 2 Trials
23
SAR236553 on Top of Atorvastatin in Primary Hypercholesterolemia: Phase 2
24
Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy: Phase 2 Studies
25
IV RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Doses Studied
26
Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Pooled Results
27
ODYSSEY Outcomes: Phase 3 Post-ACS With SAR236553
28
Program Summary
29
Thank you for participating in this activity.
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.